Investigational drug · Phase 2
DWN12088
Also called: DWN12088 Xmg
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "DWN12088"
First trial start
2022
Jul 29, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DWN12088", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "DWN12088" as an intervention, largest first.
- Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPFPivotal-lookingActive, not recruiting
Daewoong Pharmaceutical Co. LTD.Industry
NCT05389215 · 102 participants (planned) · Start Jul 29, 2022 · Primary completion Oct 13, 2026
Drug: DWN12088; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Mesa, Arizona; Phoenix, Arizona; San Francisco, California · 30 sites in all
Daewoong Pharmaceutical Co. LTD.Industry
NCT04888715 · 48 participants · Start Jul 23, 2021 · Primary completion Aug 2, 2021
Drug: DWN12088; Pirfenidone and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Seongnam-si, South Korea
Daewoong Pharmaceutical Co. LTD.Industry
NCT04767815 · 36 participants · Start Mar 22, 2021 · Primary completion May 31, 2021
Drug: Diet A group; Diet B group and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Seoul, South Korea
Daewoong Pharmaceutical Co. LTD.Industry
NCT04888728 · 24 participants · Start Jun 30, 2021 · Primary completion Jul 12, 2021
Drug: DWN12088; Nebivolol and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Busan, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Prolyl-tRNA synthetase inhibitor as a novel first-in-class keloid treatment: downregulation of de novo collagen synthesis and inflammatory cascade.
Min S, Kim KM, Hwang J, et al. · Br J Dermatol 2025
- EPRS1-mediated fibroblast activation and mitochondrial dysfunction promote kidney fibrosis.
Son SS, Jeong HS, Lee SW, et al. · Exp Mol Med 2024
- DWN12088, A Prolyl-tRNA Synthetase Inhibitor, Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis.
Lee DK, Jo SH, Lee ES, et al. · Diabetes Metab J 2024
- Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl-tRNA synthetase 1.
Yoon I, Kim S, Cho M, et al. · EMBO Mol Med 2023
Also in development for Idiopathic Pulmonary Fibrosis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Inhaled TreprostinilLIQ861 Inhaled Treprostinil, Inhaled prostacyclinPhase 35 trials
United Therapeutics · Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- BMS-986278AdmilparantPhase 33 trials
Bristol Myers Squibb · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
- HEC585Phase 33 trials
Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- BI 1015550Phase 32 trials
Boehringer Ingelheim · Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis
- DeupirfenidonePhase 32 trials
PureTech · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- INS018_055Phase 32 trials
InSilico Medicine Hong Kong Limited · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- REGEND001Phase 32 trials
Regend Therapeutics · COPD (Chronic Obstructive Pulmonary Disease), Idiopathic Pulmonary Fibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.